PRLD:NASDAQ, Prelude Therapeutics Incorporated

PRLD stock overview

Prelude Therapeutics Incorporated (PRLD:NASDAQ) closed at $3.36 on October 15, 2026, up 4.02% on the day. The stock trades 50.8% below its 52-week high of $6.83 and 189.7% above its 52-week low of $1.16. Over the past year, it gained 137.5%. Prelude Therapeutics Incorporated is part of the Health Care sector.

Key figures

Price

$3.36

Day change

+4.02%

Volume

279,283

Average volume

483,395

Market cap

268M+

52-week range

$1.16 – $6.83

50-day average

$4.86

200-day average

$3.95

Performance

Price action over the past year

In 252 trading sessions since October 14, 2025, PRLD closed higher on 129 days (51%). Its best day was November 3, 2025 (+150.31%) and its worst was November 4, 2025 (-55.78%). The stock moved 10% or more in a single session 39 times. It opened at least 5% above the previous day's high 3 times.

Recent signals

• Oct 14, 2026: Down 25.7% over 30 days, from $4.52 (Dips & Crashes scanner)
• Oct 14, 2026: Hit a new 6-Month Low of $3.23 (New Highs/Lows scanner)
• Oct 13, 2026: News catalyst: Patnership (News Catalysts scanner)

PRLD news

• Oct 15, 2026: Eli Lilly (LLY) Reported One Year Steroid Free Control In Difficult IBD
• Oct 13, 2026: Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
• Oct 13, 2026: Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
• Oct 13, 2026: Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio and Inluriyo in Patients with HR+/HER2- Breast Cancer
• Sep 11, 2026: Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
• Sep 10, 2026: Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
• Aug 12, 2026: Sellas' Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
• Aug 12, 2026: Sellas Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global Analyst Sees About 200% Upside Potential

About Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Find more stocks like PRLD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.